Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 200-774-1 | CAS number: 72-19-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEL
- 900 mg/kg bw/day
- Study duration:
- subchronic
- Species:
- rat
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
In a subchronic toxicity study (2003 -0842 -FGT) according to OECD TG 408 L-threonine was administered to rats in doses of 0 (control), 0.5, 1.5 and 5.0% in diet. Each group consisted of 10 rats/sex, the control group consisted of 20 rats/sex. Administration of the test substance did not reveal any treatment-related and toxicological relevant change in low- and mid-dose animals. However, in high-dose animals an increase in kidney weights and increased heart weights were considered to be treatment related. Although the observed changes were rather minor and histopathological examinations revealed no abnormalities, they were considered toxicologically relevant. The NOAEL after daily administration of L-threonine for 13 consecutive weeks can conservatively be placed at a dietary level of 1.5 % (equivalent to a mean test substance intake of 916 mg/kg bw in males and 962 mg/kg bw in females).
In a second subchronic toxicity study (2009 -0252 -FGT) according to OECD TG 408 L-threonine was administered to rats in doses of 0 (control), 0.5, 1.5 and 5.0% in diet. The diets were fed ad libitum to Wistar rats (10 rats/sex/group) during 13 weeks, and provided an overall intake of 0.3, 0.9 and 3.0 g/kg body weight/day for males, and 0.3, 1.0 and 3.2 g/kg body weight/day for females
Based on the increase in relative kidney weight in the high-dose group, the NOAEL of L-Threonine was conservatively placed at the mid-dose level (1.5%). This level was equivalent to an overall intake of at least 0.9 g /kg body weight/day.
In a further subchronic toxicity study (94 -0630 -FGT) similar to OECD TG 408 L-threonine was administered to rats in doses of 0 (control group: basic diet), 1.25, 2.5 and 5.0% L-threonine in diet. Each group consisted of 12 or 18 male and female rats respectively. Even the highest dose used (5%) resulting in an average intake of 3266.9 and 3673.3 mg/kg bw for male and female, respectively produced no adverse effects and is therefore regarded as the NOAEL. However, a reliability score of 4 was assigned to this study and was used only as a supporting study as the full study report was not available to the registrant (only a summary of the results).
In a subacute toxicity study (2002 -0140 -DGT) according to OECD TG 407 performed under GLP L-threonine was given by gavage to 10 animals /dose (5 rats/sex) in doses of 100, 300, and 1000 mg/kg bw. The resulting NOAEL was 1000 mg/kg bw.
This result was confirmed in a publication (van de Mortel et al 2010). According to this publication l-threonine caused no adverse effects at a dose of 1000 mg/kg bw in a study according to OECD 407.
There are no studies available regarding repeated dose toxicity via the dermal route and via the inhalative route. However, although oral intake is not the most appropriate route of exposure it represents a worst case scenario in terms of bioavailability. No evidence for local effects is given. Therefore and due to animal welfare there is no need for further inhalative or dermal repeated dose testing.
Justification for selection of repeated dose toxicity via oral route - systemic effects endpoint:
conservative approach - repeated dose study with toxicological relevant effects at lowest dose
Justification for classification or non-classification
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.